New blood test could spot sepsis in newborns faster

NCT ID NCT07670624

Not yet recruiting Diagnosis Sponsor: Salzburger Landeskliniken Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 31, 2026 · Updated 2 times

Summary

This study will test a new biomarker called t6A to see if it can help doctors diagnose bacterial infections in newborn babies early. Researchers will measure t6A levels in 210 infants who need blood tests for suspected infection. The goal is to find a more accurate way to detect sepsis, which could lead to quicker treatment and fewer unnecessary antibiotics.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: N6-threonylcarbamoyladenosine (t6A) biomarker test
What this could lead to: If successful, this could provide a faster, more accurate way to diagnose bacterial infections in newborns, potentially reducing unnecessary antibiotic use and improving outcomes.
What could go wrong: This is an early study with 210 participants and has not yet started recruiting. The biomarker may not prove reliable enough to replace current methods, and results may not apply to all newborns.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIOMARKER DISCOVERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis neonatal sepsis Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIOMARKER DISCOVERY NEWBORN SEPSIS SEPSIS

Contacts and locations

Locations

Wroclaw Medical University

Wroclaw, 50367, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.